Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Natera Inc    NTRA

NATERA INC (NTRA)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 10/16 10:00:00 pm
21.22 USD   +4.74%
08/08NATERA : 2Q Earnings Snapshot
AQ
08/08NATERA : Reports Second Quarter 2018 Financial Results
PR
08/01NATERA : Inc. Announces Second Quarter 2018 Earnings Conference Call
PR
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2018 10/11/2018 10/12/2018 10/15/2018 10/16/2018 Date
20.86(c) 20.11(c) 20.77(c) 20.26(c) 21.22(c) Last
1 159 074 952 701 461 912 628 619 582 529 Volume
-3.65% -3.60% +3.28% -2.46% +4.74% Change
More quotes
Financials (USD)
Sales 2018 263 M
EBIT 2018 -107 M
Net income 2018 -124 M
Finance 2018 15,4 M
Yield 2018 -
Sales 2019 310 M
EBIT 2019 -69,9 M
Net income 2019 -83,0 M
Finance 2019 4,37 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 4,75x
EV / Sales2019 4,06x
Capitalization 1 266 M
More Financials
Company
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services.It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception,... 
More about the company
Surperformance© ratings of Natera Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on NATERA INC
09/15NATERA : Signs Agreement with Bristol-Myers Squibb to Investigate Signatera ctDN..
AQ
09/12NATERA, INC. : Other Events (form 8-K)
AQ
08/09NATERA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/08NATERA : 2Q Earnings Snapshot
AQ
08/08NATERA, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/08NATERA : Reports Second Quarter 2018 Financial Results
PR
08/01NATERA : Inc. Announces Second Quarter 2018 Earnings Conference Call
PR
07/31NATERA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/13NATERA, INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
07/12NATERA : Announces Pricing of Follow-On Offering
PR
More news
Sector news : Diagnostic & Testing Substances
10/16STRATEGY : Has being defensive paid off since the 2008 crisis?
10/16ABBVIE : The Strategies AbbVie Employed to Protect Humira From Copycats
DJ
10/15ABBOTT LABORATORIES : Names Robert B. Ford President, Chief Operating Officer
DJ
10/15ConvaTec shares plunge on profit warning and CEO departure
RE
10/10MEDTRONIC : Gets Regulatory Approval for Insulin Pump
DJ
More sector news : Diagnostic & Testing Substances
Latest Tweets
10/13Natera $NTRA Downgraded by Zacks Investment Research to “Sell”  
10/11TheStreet Lowers Natera $NTRA to D+  
10/09#HedgeFund and #InsiderTrading #News: Bill Ackman, Trian Fund Management, $VT.. 
10/09JPMorgan Chase & Co. Begins Coverage on Natera $NTRA  
10/09Get the latest news and updates for $NTRA $BXC $RBCAA $FRF $POM automatically.. 
More tweets
Qtime:69
News from SeekingAlpha
10/12Waiting For The Chips To Fall - The Idea Guide 
10/09NATERA : Remain Short, Risks Still High At These Levels Into More Challenging 20.. 
10/05After Hours Gainers / Losers (10/05/2018) 
10/05Premarket analyst action - healthcare 
09/27Small Companies With Superior Growth And Strong Momentum 
Chart NATERA INC
Duration : Period :
Natera Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 26,8 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Matthew Rabinowitz Chairman, President & Chief Executive Officer
Stephen Chapman Chief Operating Officer
Michael Brophy Chief Financial Officer
Jonathan Sheena Director & Chief Technology Officer
Cheng-Ho Lin Chief Scientific Officer-Oncology
Sector and Competitors
1st jan.Capitalization (M$)
NATERA INC125.36%1 266
BIOMÉRIEUX-15.38%8 654
DIASORIN SPA7.43%5 146
AUTOBIO DIAGNOSTICS CO LTD3.34%3 336
SIEGFRIED HOLDING AG21.14%1 680
MACCURA BIOTECHNOLOGY CO LTD--.--%1 385